Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: Findings of the PRIAMHO-II registry;Efecto de la asociación de bloqueadores beta e inhibidores de la enzima de conversión en la supervivencia al año tras un infarto agudo de miocardio. Resultados del registro PRIAMHO II

Revista Espanola de Cardiologia

Volumn 59, Issue 4, 2006, Pages 313-320

  Arós, Fernando ^a   Loma Osorio, Ángel ^a   Villa, Joan ^b   López Bescós, Lorenzo ^c   Cuñat, José ^d   Rodríguez, Emilio ^e   San José, José M ^f   Heras, Magda ^g   Marrugat, Jaume ^b  

^a HOSPITAL TXAGORRITXU   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e Hospital Santa Maria Nai   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Angiotensin converting enzyme inhibitors; Beta blockers; Myocardial infarction; Survival

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC ACID DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG POTENTIATION; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HOSPITAL DISCHARGE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; ST SEGMENT ELEVATION; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 33744825706     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13087059     Document Type: Article

References (27)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
2. Hennekens CM, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjuntive drug therapy of acute myocardial infarction. Evidence from clinical trials. N Engl J Med. 1996;335:1660-7.
3. Fremantale N, Cleland J, Young P, Mason J, Harrison J. β-blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730-6.
4. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, et al, for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE inhibitor therapy in patients with heart failure or left ventricular dysfunction: a systematic overview of data from individual patientes. Lancet. 2000;355:1575-81.
5. Braunwald E, Antman EM, Beasly JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062.
6. Braunwald E, Antman EM, Beasly JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol. 2002:40:1366-74.
7. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28-66.
8. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/ AHA guidelines for the management of the management of patientes with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines. Circulation. 2004;110:588-636.
9. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, et al. Docuemento de expertos sobre el uso de inhibidores de la enzima de conversión de la angiotensina en la enfermedad cardiovascular. Grupo de Trabajo sobre inhibidores de la enzima de conversión de la angiotensina de la Sociedad Europea de Cardiología. Rev Esp Cardiol. 2004;57:1213-32.
10. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a cardiac hospitalization atherosclerosis management program (CHAMP). Am J Cardiol. 2001;87:819-22.
11. Burwen DR, Galusha DH, Lewis JM, Bedinger MR, Radford MJ, Krumholz HM, et al. National and state trends in quality of care for acute myocardial infarction between 1994-5 and 1998-99. The Medicare health care quality improvement program. Arch Intern Med. 2003;163:1430-9.
12. Mukherjeee D, Fang J, Chetcutti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation. 2004;109:745-9.
13. Muñiz García J, Gómez Doblas JJ, Santiago Pérez MI, De Teresa Galván E, Cruz Fernández JM, Castro Beiras A, en representación del Grupo de Trabajo del Proyecto CAM. Efecto de un programa sencillo de educación de los profesionales en el cumplimiento de medidas de prevención secundaria en el momento del alta hospitalaria tras un síndrome coronario agudo. Proyecto CAM. Rev Esp Cardiol. 2004;57:1017-28.
14. The Capricorn investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfuncfion: the CAPRICORN randomised trial. Lancet. 2001;357:1385-90.
15. Arós F, Cuñat J, Loma-Osorio A, Torrado E, Bosch X, Rodríguez JJ, et al. Tratamiento del infarto agudo de miocardio en España en el año 2000. El estudio PRIAMHO II. Rev Esp Cardiol. 2003;56:1165-73.
16. Rosenbaum PR, Rubin DR. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
17. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328-428.
18. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-53.
19. The EURopean trial On reduction of cardiac events with Perindropil in stable coronary Artery Investigators. Efficacy of perindropil in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-8.
20. The PEACE trial investigators. Angiotensin-converting-enzime inhibition in stable coronary disease. N Engl J Med. 2004;351: 2058-68.
21. Hippisley-Cox J, Coupland C. Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis. BMJ. 2005;330:1059-68.
22. Gluckman TJ, Sachdev M, Schulman SP, Blumenthal RS. A simplified approach to the management of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;19:349-57.
23. Yusuf S, Pogue J. ACE inhibition in stable coronary artery disease. N Engl J Med. 2005;352:937-8.
24. Schiele F, Meneveau N, Seronde MF, Caulfield F, Fouche R, Lassabe G, et al on behalf of the Réseau de Cardiologie de Franche Comté group. Compliance with guidelines and 1-year mortality in patients with acute myocardial infarction: a prospective study. Eur Heart J. 2005; 26:873-80.
25. Shlipak MG, Browner WS, Noguchi H, Massie B, Frances CD, McClellan M. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in eldely patients with reduced left ventricular function afte myocardial infarction. Am J Med. 2001;110:425-33.
26. Poole-Wilson P, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M, et al. for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): randomised controlled trial. Lancet. 2003;362:7-12.
27. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000; 36:959-69.